Johannes Kleemann

5PUBLICATIONS
12CO-AUTHORS
Predictive and prognostic markersHuman information interaction and retrievalCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 14, 2023
Analytical Validation of an Immunohistochemical 7-Biomarker Prognostic Assay (immunoprint®) for Early-Stage Cutaneous Melanoma in Archival Tissue of Patients with AJCC v8 T2-T3 Disease.

Mirjana Ziemer, Beate Weidenthaler-Barth, Philipp Gussek

|Jul 17, 2022
Exploring the most visible websites on cutaneous T-cell lymphoma-revealing limited quality of patient health information on the internet.

D Özistanbullu, R Weber, J Kleemann

|May 16, 2022
Impact of the Covid-19 pandemic on melanoma and non-melanoma skin cancer inpatient treatment in Germany - a nationwide analysis.

J Kleemann, M Meissner, D Özistanbullu

|Jun 02, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.

Henner Stege, Maximilian Haist, Michael Schultheis

|Aug 30, 2019
G protein-coupled receptor 40 expression in human melanoma - correlation with tumour thickness, AJCC stage and survival.

J Kleemann, I Hrgovic, P Kleimann

Pageof 1

Frequent Collaborators

3 joint publications

S Kippenberger

2 joint publications

Stephan Grabbe

1 joint publications

Maximilian Haist

1 joint publications

Michael Schultheis